Novartis clinicaltrials.gov records update across scleroderma, urticaria and SMA studies

Novartis Pharmaceuticals had three clinicaltrials.gov records with last updates posted on October 13, 2026, none of which show posted efficacy or results data.

• A Phase 2 study of ianalumab in diffuse cutaneous systemic sclerosis is active not recruiting, with an actual start of October 9, 2024 and an estimated primary completion of July 30, 2027¹. The trial enrolled 201 participants and is testing whether ianalumab is superior to placebo¹ on a primary outcome of 3/5 rCRISS25 response at Week 52¹.
• A Phase 3b study, acronym RECLAIM, comparing remibrutinib to dupilumab in chronic spontaneous urticaria is active not recruiting, having started July 11, 2025, with an estimated primary completion of February 22, 2027². The study enrolled 409 participants² and measures absolute change from baseline in Weekly Urticaria Activity Score (UAS7) at Week 4².
• A retrospective chart review of onasemnogene abeparvovec (Zolgensma) in spinal muscular atrophy type 1 patients in Saudi Arabia is not yet recruiting, with an estimated start of November 1, 2026 and estimated completion November 25, 2026³. The observational study plans to enroll 6 participants³ and will track the proportion of non-sitter patients achieving independent sitting for at least 30 seconds at any visit up to 12 months after treatment³.